Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

August 04, 2022

Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera.

July 25, 2022

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

May 10, 2022

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

May 09, 2022

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

May 05, 2022

Marcela Mazo Canola, MD, discusses pivotal trials in early-stage and metastatic HER2-positive breast cancer, plus ongoing trials to watch.

May 04, 2022

Ruben A. Mesa, MD, discusses the different disparities that are known to affect cancer care and key efforts being made to address them.

May 04, 2022

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

May 03, 2022

Ruben A. Mesa, MD, discusses various determinants of disparities in cancer care.

April 12, 2022

March 31, 2022

Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.

February 10, 2022

Ruben A. Mesa, MD, discusses the importance of community engagement to facilitate optimal care in oncology.

January 21, 2022

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.

January 13, 2022

Ruben A. Mesa, MD, discusses JAK inhibitors and other promising agents in the myelofibrosis therapeutic landscape.

December 06, 2021

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

November 19, 2021

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

May 24, 2021

Dr. Kaklamani discusses current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.

May 11, 2021

Sherri Cervantez, MD, discusses the utility of osimertinib in non–small cell lung cancer, as well as remaining questions regarding the treatment of patients who develop resistance to the third-generation EGFR inhibitor.

February 04, 2021

Dr. Mesa and Dr. Gerds provide insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.

January 06, 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

December 07, 2020

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.